Medicare drug coverage

Nucala: 2027 Medicare Part D coverage

5,445 of 5,495 Part D plans (99%) list Nucala on their 2027 formulary, up 51 points from 2026. 100% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Nucala is number 133 by total Medicare Part D spending in 2024 ($318 million). Plans that list it most often put it on tier 5. Counts use 5 RxNorm products for this name.

Nucala Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it2,665 (48%)5,445 (99%)+51 points
Prior authorization (of plans that list it)2,665 (100%)5,438 (100%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)2,474 (93%)5,309 (98%)+5 points
Any of the three (of plans that list it)2,665 (100%)5,445 (100%)no change
Not listed or restricted (of all plans)5,518 (100%)5,495 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Nucala formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1105 (4%)114 (2%)
Tier 22 (0%)1 (0%)
Tier 447 (2%)46 (1%)
Tier 52,511 (94%)5,284 (97%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 49 of them (1%) added prior authorization, step therapy, or a quantity limit for Nucala, and 2 stopped listing it.

Nucala: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20272 (0%)
Listed it in 2027, not in 20262,138 (49%)
Moved it to a higher tier23 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit49 (1%)
Added at least one of the three49 (1%)
Removed at least one of the three1 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Nucala off the formulary or list it with prior authorization, step therapy, or a quantity limit. Alaska ranks first at 100%, with 100% of its plans using prior authorization or step therapy; New York ranks last at 100%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Nucala, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Alaska9100%100%no change
2Alabama115100%100%no change
3Arizona148100%100%no change
4California397100%100%no change
5Connecticut54100%100%no change
6District of Columbia21100%100%no change
7Delaware43100%100%no change
8Georgia151100%100%no change
9Hawaii50100%100%no change
10Iowa64100%100%no change
11Idaho45100%100%no change
12Illinois133100%100%no change
13Indiana140100%100%no change
14Kansas84100%100%no change
15Kentucky123100%100%no change
16Louisiana126100%100%no change
17Massachusetts92100%100%no change
18Maryland49100%100%no change
19Maine52100%100%no change
20Michigan183100%100%no change
21Minnesota63100%100%no change
22Missouri171100%100%no change
23Montana27100%100%no change
24North Carolina177100%100%no change
25North Dakota26100%100%no change
26Nebraska51100%100%no change
27New Hampshire25100%100%no change
28New Jersey74100%100%no change
29New Mexico68100%100%no change
30Ohio173100%100%no change
31Oklahoma81100%100%no change
32Oregon92100%100%no change
33Pennsylvania324100%100%no change
34Rhode Island29100%100%no change
35South Carolina91100%100%no change
36South Dakota30100%100%no change
37Tennessee157100%100%no change
38Texas412100%100%no change
39Virginia145100%100%no change
40Vermont14100%100%no change
41Washington114100%100%no change
42Wisconsin97100%100%no change
43West Virginia70100%100%no change
44Wyoming13100%100%no change
45Florida549100%100%no change
46Nevada100100%97%no change
47Arkansas86100%97%no change
48Colorado106100%96%no change
49Mississippi105100%96%no change
50Utah53100%94%no change
51New York215100%90%no change

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Nucala off or restrict it.

Nucala coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.884100%100%100%no change0
UnitedHealth Group, Inc.850100%100%100%no change0
Devoted Health, Inc.728100%100%100%no change0
CVS Health Corporation633100%100%100%no change0
Elevance Health, Inc.294100%100%100%no change0
Centene Corporation268100%100%100%no change0
Health Care Service Corporation231100%100%100%no change0
Kaiser Foundation Health Plan, Inc.112100%100%100%no change0
Highmark Health98100%100%100%no change0
SCAN Group85100%100%100%no change0
Alignment Healthcare USA, LLC77100%100%100%no change0
Guidewell Mutual Holding Corporation5569%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.43100%100%100%no change43
Molina Healthcare, Inc.43100%100%100%no change0
Corewell Health40100%100%100%no change0
Zing Health Consolidator, Inc36100%100%100%no change0
CAPITAL BLUE CROSS35100%100%100%no change0
Medica Holding Company31100%100%100%no change0
UPMC Health System30100%100%100%no change0
Universal Health Services, Inc.29100%100%100%no change0
MHH Healthcare, L.P.26100%100%100%no change0
Independence Health Group, Inc.25100%100%100%no change0
Point32Health, Inc.23100%100%100%no change0
BlueCross BlueShield of Tennessee22100%100%100%no change0
California Physicians' Service22100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Nucala?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing